S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Celgene to Present Long-Term Efficacy and Safety Data on Oral OTEZLA® (apremilast) in Plaque Psoriasis and Psoriatic Arthritis at European Academy of Dermatology and Venereology Congress|
|Celgene Corporation to Present at Investor Conferences in September|
|Bristol-Myers Squibb and Celgene Enter Clinical Collaboration Agreement to Evaluate Immunotherapy and Chemotherapy Combination Regimen|
|Zeldes Haeggquist & Eck, LLP Announces Investigation of Celgene, Inc. (2014/9/22)|
|Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplant Published in New England Journal of Medicine|
|Celgene Reports Second Quarter 2014 Operating and Financial Results|
|Celgene Corporation to Announce Third Quarter 2014 Results on October 23, 2014|
|VentiRx Pharmaceuticals Provides Corporate and Clinical Update (2014/9/2)|
|Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration|
|Celgene shares up on news of positive late-stage drug trial|
Click above to view more mutual fund data and stats for celg - Celgene Corp.